Fanny E. Palumbo

Catania, 95123, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications

Three-Hour Infusion of Methotrexate at 3 g/m2 With or Without Intrathecal Chemotherapy Significantly Reduces CNS Relapses and Improves Survival in Patients With Large B-Cell Lymphomas at Increased CNS Risk.

Three-Hour Infusion of Methotrexate at 3 g/m2 With or Without Intrathecal Chemotherapy Significantly Reduces CNS Relapses and Improves Survival in Patients With Large B-Cell Lymphomas at Increased CNS Risk.

Journal: American journal of hematology
Published: December 18, 2025

BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders.

BTK Inhibition in Hematology: From CLL/SLL to Emerging Applications Across B-Cell and Immune Disorders.

Journal: Biomolecules
Published: December 16, 2025

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal
Published: December 04, 2025

Endovascular management of pelvic congestion syndrome in males: A report of 2 cases.

Endovascular management of pelvic congestion syndrome in males: A report of 2 cases.

Journal: Radiology case reports
Published: November 27, 2025

Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database.

Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database.

Journal: Pharmaceuticals (Basel, Switzerland)
Published: November 22, 2025

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

NPM1 and IDH1/2 Mutations Show Limited Prognostic Impact in Relapsed/Refractory AML: Evidence From the AVALON Cohort.

Journal: Hematological oncology
Published: November 10, 2025

Benign purpuric cutaneous eruption in a young patient with AML treated with CPX-351.

Benign purpuric cutaneous eruption in a young patient with AML treated with CPX-351.

Journal: Leukemia & lymphoma
Published: October 31, 2025

Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance Database.

Vitamin K Antagonists (VKAs) and Novel Oral Anticoagulants (NOACs) Safety Comparison Based on Data from EudraVigilance Database.

Journal: Hematology reports
Published: September 13, 2025

Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.

Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: safety and efficacy.

Journal: Annals of hematology
Published: August 30, 2025

Hodgkin-Inflammatory-Based Model ME-IPS Is a New Inflammatory-Based Prognostic Model Calculated at Diagnosis: Results From a Real-Life Study.

Hodgkin-Inflammatory-Based Model ME-IPS Is a New Inflammatory-Based Prognostic Model Calculated at Diagnosis: Results From a Real-Life Study.

Journal: European journal of haematology
Published: August 26, 2025

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.

Journal: American journal of hematology
Published: August 08, 2025

Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.

Journal: Blood cancer journal
Published: July 29, 2025
Showing 1-12 of 23

Last Updated: 09/26/2026